Global /South Korea /Healthcare /Biotechnology /456160

G2GBIO Inc.

456160

• KRX: 456160 • Delayed

84,900KRW 7.5%

55.63 USD

As of 12 June 2026, G2GBIO Inc. has a market cap of $923.65M USD, ranking #11151 globally and #301 in South Korea. It ranks #1010 in the Healthcare sector, and #190 in the Biotechnology industry.

Global Rank

11151

Country Rank

301

Sector Rank

1010

Industry Rank

190

Key Stats

Market Cap

$923.65MUSD

1.4T KRW

Company Profile

Country (HQ)

South Korea

Sector

Healthcare

Industry

Biotechnology

CEO

Hee-yong Lee open_in_new

Founded

2017

Website

g2gbio.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
7.5%	13%	7.7%	-0.1%	45%	27%	57%	57%	57%

News

Markets

Exchange	Ticker	Price	Quotes
Korea Exchange (KRX) MIC: XKRX PRIMARY	456160 ISIN: KR7456160001 Shares Out.: Shares Outstanding: 16.629M¹ Shares Float: 12.269M² TV: TradingView: KRX: 456160 SA: Stock Analysis: KRX: 456160 YF: Yahoo Finance: 456160.KS GF: Google Finance: KRX: 456160 BA: Barron's: 456160 MS: Morningstar: XKRX: 456160	84,900 KRW	TV: TradingView: KRX: 456160 SA: Stock Analysis: KRX: 456160 YF: Yahoo Finance: 456160.KS GF: Google Finance: KRX: 456160 BA: Barron's: 456160 MS: Morningstar: XKRX: 456160

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About G2GBIO Inc.

G2GBIO Inc., a clinical-stage biotech company, provides pharmaceutical products. The company’s pipeline products include GB-5001, GB-5001A, and GB-5112 for the treatment of Alzheimer’s disease; GB-6002, an opioid drug that is used for post-operative pain treatment; GB-7001 for type-2 diabetes treatments; GB-5313 for the treatment of Osteoarthritis; GB-7101 and GB-7103 for the treatment of prostate cancer; GB-6201 and GB-6203 for androgenetic alopecia treatments; and GH-001 for the treatment of Hepatitis B. It also develops GB-2001 for animal castration; and GB-2006, an animal postoperative pain relief drug, which is in clinical trial stage. The company was founded in 2017 and is headquartered in Cheongju-si, South Korea.

Similar Companies

Industry: Biotechnology (South Korea)

Name	Market Cap (USD) diff.	PE	Country
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 5K%	35.5	South Korea
Celltrion, Inc. KRX: 068270	$28.11B 42.76T KRW 3K%	43.8	South Korea
ALTEOGEN Inc. KRX: 196170	$13.37B 20.33T KRW 1K%	146.6	South Korea
HLB Co., Ltd. KRX: 028300	$5.51B 8.37T KRW 496%	-	South Korea
Peptron, Inc. KRX: 087010	$3.99B 6.07T KRW 332%	-	South Korea
SK bioscience Co.,Ltd. KRX: 302440	$2.25B 3.42T KRW 144%	-	South Korea

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 20K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 17K%	19.0	United States
argenx SE EBR: ARGX	$47.8B 41.39B EUR 5K%	39.9	Netherlands
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 4K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.17B 33.71B CHF 4K%	37.2	Switzerland
Natera, Inc. NASDAQ: NTRA	$27.6B 3K%	-	United States

chevron_leftBack